Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | NPC1 | O15118 | 2/20 | 0.66 |
| ▸ | RAB9A | P51151 | 2/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.63 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.63 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.63 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.63 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.63 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 2/20 | 0.58 |
| ▸ | RECQL | P46063 | 2/20 | 0.58 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | BCHE | P06276 | 1/20 | 0.58 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.58 |
| ▸ | ACHE | P22303 | 1/20 | 0.58 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7666658 | 1.00 | MAPT (0.66) | MAPTNPC1RAB9ATDP1HDAC1 | |
| SCHEMBL5425525 | 0.89 | HDAC3 (0.54) | MAPTNPC1RAB9ATDP1HDAC1 | |
| SCHEMBL8562018 | 0.89 | NPC1 (0.57) | MAPTNPC1RAB9ATDP1HDAC1 | |
| SCHEMBL5425520 | 0.89 | HDAC3 (0.54) | MAPTNPC1RAB9ATDP1HDAC1 | |
| SCHEMBL29060766 | 0.86 | HDAC2 (0.76) | MAPTNPC1RAB9ATDP1HDAC1 | |
| SCHEMBL4029206 | 0.86 | HDAC2 (0.76) | MAPTNPC1RAB9ATDP1HDAC1 | |
| SCHEMBL8559227 | 0.85 | ALDH1A1 (0.78) | MAPTNPC1RAB9ATDP1HDAC1 | |
| SCHEMBL9177259 | 0.85 | EGFR (0.55) | MAPTNPC1RAB9ATDP1HDAC1 | |
| SCHEMBL9177257 | 0.85 | EGFR (0.55) | MAPTNPC1RAB9ATDP1HDAC1 | |
| SCHEMBL28440928 | 0.84 | HDAC2 (0.73) | MAPTNPC1RAB9ATDP1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116606247-A | Imide compound and preparation method and application thereof | 温州医科大学 | 2023-08-18 | — | — | CN | disclosed |
| CN-107162928-B | Halogenated analogs of anti-fibrotic agents | 塞尔塔医疗有限公司 | 2022-03-11 | — | — | CN | disclosed |
| EP-3045170-B1 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2018-07-04 | — | — | EP | disclosed |
| CN-107162928-A | The halogenated analogues of antifibrotic agents | 法博太科制药有限公司 | 2017-09-15 | — | — | CN | disclosed |
| EP-3045170-A1 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | Fibrotech Therapeutics PTY LTD (AU) | 2016-07-20 | — | — | EP | disclosed |
| EP-2220028-B1 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2016-03-09 | — | — | EP | disclosed |
| US-8624056-B2 | Halogenated analogues of anti-fibrotic agents | FIBROTECH THERAPEUTICS PTY LTD | 2014-01-07 | — | — | US | disclosed |
| US-20120059188-A9 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | THE UNIVERSITY OF MELBOURNE (AU) | 2012-03-08 | — | — | US | disclosed |
| US-20110021815-A1 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2011-01-27 | — | — | US | disclosed |
| WO-2010144959-A1 | ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2010-12-23 | — | — | WO | disclosed |
| EP-2220028-A1 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | Fibrotech Therapeutics PTY LTD (AU) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009079692-A1 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059188-A9 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | MMP1, FIBP, HDGF | MAPT 4850/4885NPC1 1501/4885RAB9A 1799/4885 |
| US-20110021815-A1 | HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS | MMP1, FIBP, HDGF | MAPT 4850/4885NPC1 1501/4885RAB9A 1799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.